Studies have reported the in vitro effects of the SERPINE1 inhibitor Tiplaxtinin in gliomas, but there is no application of this inhibitor in glioma in vivo models, which may be related to the drug’s permeability across the blood-brain barrier (31). The gene discussed is SERPINE1; the disease is central nervous system cancer.